Redeye comment on the EMA’s negative trend vote on Biogen’s aducanumab and what it means for AlzinovaDate: 2021-11-19
"Yesterday, Biogen received a negative trend vote on the aducanumab (Aduhelm) Marketing Authorization application, following an oral explanation held at the November meeting of the EMA’s CHMP (Committee for Medicinal Products for Human Use). The CHMP will adopt a formal opinion at its December meeting (December 13-16, 2021). Our view, however, is that a rejection is the most likely outcome."
“Even though we have argued that that external passive Aβ immunotherapies showing encouraging results validate the amyloid hypothesis, and thus further strengthen Alzinova’s approach, we want to reiterate that Alzinova’s vaccine candidate ALZ-101 is vastly differentiated from its peers.
We believe that the candidate’s oligomer-specific vaccine approach could offer a superior administration-friendly and cost-effective alternative to other Alzheimer’s treatments. We recently published a research update where we provide a thorough deep-dive into the current Alzheimer’s treatment pipeline and what makes ALZ-101 stand out (here).”
We believe that the EMA’s pending decision should not alter investors’ view of Alzinova, or the likelihood of ALZ-101 reaching the market. We maintain our Base Case valuation of SEK 22 per share.”